Sign Out
Prostate cancer: Treatment of locally advanced or metastatic prostate cancer.
A favourable effect of the treatment is all the more pronounced and more frequent if the patient has not previously received any other hormone treatment.
3.75 mg- and 11.25 mg-vial: Genital and extragenital endometriosis (stage I to IV): Treatment should not be administered for more than 6 months (see Adverse Reactions). It is not recommended to undertake a second course of treatment by triptorelin or by another GnRH analogue.
3.75 mg-vial only: Prostate cancer: Treatment of high-risk localised or locally advanced prostate cancer in combination with radiotherapy. See Pharmacology: Pharmacodynamics under Actions.
Central precocious puberty: Before 8 years in girls and 10 years in boys.
Female infertility: Complementary treatment in association with the gonadotrophins (hMG, FSH, hCG) in the course of ovulation induction in view of in vitro fertilisation and embryo transfer (I.V.F.E.T.).
Treatment of uterine fibromyomas prior to surgery: Associated with anaemia (haemoglobin less than or equal to 8 g/dl).
When a reduction in the size of fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery.
The treatment duration is restricted to 3 months.
Breast cancer: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy (see Contraindications, Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
